Director Jon Halbert purchases 68,000 shares of Caris Life Sciences at $14.56; now holds 704,598 shares (+10.7%).
Jon Halbert, a director of Caris Life Sciences, acquired 68,000 shares at $14.56 on 2026-05-15, expanding his holdings by 10.7% to 704,598 shares total. The transaction occurred at a price that sits near the lower end of the 52-week range ($14.19–$42.50) and represents a $990,080 commitment. The company reported Revenue $216,174,000.00 for the latest quarter and Annual revenue growth (FY vs prior FY) of +97.0%, but remains unprofitable with Net income of $-510,000.00 and a full-year negative net income, reflected in an elevated P/E of 141.58. The stock is currently -60.0% from its 52-week high, suggesting the purchase occurred during a period of material price weakness relative to recent trading history. This substantial share acquisition by a director during a period of depressed valuation and significant revenue expansion, though from an unprofitable base, merits monitoring of the underlying business trajectory and capital allocation decisions.